About US
Contact us
-
EU IMI launches new consortium to develop economic models for pharmaceutical industryA new European consortium Driving Reinvestment in research and development and Responsible Antibiotic Use (Drive AB) has been launched, to deal with the growing global threat of antibiotic resistance.2014/10/29
-
Ipsen to market telotristat etiprate outside North America and JapanFrance-based Ipsen have entered an exclusive licensing agreement with US-based Lexicon Pharmaceuticals to market telotristat etiprate outside of North America and Japan. Lexicon will hold the rights2014/10/28
-
EMA committee recommends AstraZeneca’s Lynparza to treat ovarian cancerBritish-Swedish drug maker AstraZeneca has received positive feedback for its Lynparza (olaparib) from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). CHM2014/10/28
-
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatmentJanssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA®(ibrutinib) to the U.S. Food and Drug Administration2014/10/27
-
Roche to invest $3bn to develop Basel site in SwitzerlandRoche is set to invest more than CHF3bn ($3.14bn) to develop a new research and development centre, upgrade infrastructure and renovate the existing office building at its Basel site in Switzerland.2014/10/27
-
FDA accepts Merck and Sanofi’s BLA to review paediatric hexavalent vaccineMerck and Sanofi Pasteur have received approval for review from US Food and Drug Administration (FDA) for investigational paediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB. The FDA accepted the biolo2014/10/24
-
Johnson & Johnson invests $200m to accelerate Ebola vaccine programmeUS-based Johnson & Johnson (J&J) have announced an investment of more than $200m, in a bid to speed up the Ebola vaccine programme at its Janssen Pharmaceutical companies. J&J collaborate2014/10/24
-
FDA accepts Eisai’s sNDA to review antiepileptic drug FycompaJapan-based Eisai has obtained approval for review from US Food and Drug Administration (FDA) for its antiepileptic drug Fycompa (perampanel). The FDA accepted Eisai's supplemental new drug applicati2014/10/23
-
Sanofi Pasteur and Immune Design to develop vaccine for herpes simplex virusVaccines division Sanofi Pasteur has partnered with clinical-stage immunotherapy company Immune Design to develop herpes simplex virus (HSV) immune therapy. As part of the deal, both companies will d2014/10/22
-
AstraZeneca and University of Cambridge partner for research on neurodegenerative diseasesAstraZeneca and subsidiary MedImmune have entered into four new collaborations with the University of Cambridge, expanding on their existing partnership. As part of the three year collaboration, both2014/10/22